MRK · News · 20261001N
Licensing / Collaboration Deals
Merck & Co., Inc. · 2026-10-01 · Importance 64 · Surprise 42 · In source text
Merck announced a global license agreement with SciBrunch Therapeutics for the investigational cancer drug SPR2015. The agreement includes a $400 million upfront payment and potential milestone payments of up to $2.13 billion. The potential milestone consideration exceeds the materiality threshold and represents a material future contingent commitment tied to development and commercial performance.
Key facts
- Merck & Co. announced a global license agreement with SciBrunch Therapeutics for an investigational cancer drug, SPR2015, involving a $400 million upfront payment and potential milestone payments up to $2.13 billion. source
- Merck & Co. made an upfront payment of $400 million for a license agreement. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -0.3% | Merck & Co. made an upfront payment of $400 million for a license agreement. |
| liability | negative | contingent | -0.1% | Merck & Co. announced a global license agreement with SciBrunch Therapeutics for an investigational cancer drug, SPR2015, involving a $400… |